Logo 1 Logo 2

Investigational Drug Details

Drug ID: D259
Drug Name: Remifentanil
Synonyms:
Type: small molecule
DrugBank ID: DB00899
DrugBank Description: Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depression and analgesia.
PubChem ID: 60815
CasNo: 132875-61-7
Repositioning for NAFLD: Yes
SMILES: CCC(=O)N(C1=CC=CC=C1)C1(CCN(CCC(=O)OC)CC1)C(=O)OC
Structure:
InChiKey: ZTVQQQVZCWLTDF-UHFFFAOYSA-N
Molecular Weight: 376.4467
DrugBank Targets: Mu-type opioid receptor; Delta-type opioid receptor; Kappa-type opioid receptor
DrugBank MoA: Remifentanil is a µ-opioid agonist with rapid onset and peak effect, and short duration of action. The µ-opioid activity of remifentanil is antagonized by opioid antagonists such as naloxone.
DrugBank Pharmacology: Remifentanil is an opioid agonist with rapid onset and peak effect and ultra-short duration of action. The opioid activity of remifentanil is antagonized by opioid antagonists such as naloxone. The analgesic effects of remifentanil are rapid in onset and offset. Its effects and side effects are dose dependent and similar to other opioids. Remifentanil in humans has a rapid blood-brain equilibration half-time of 1 ± 1 minutes (mean ± SD) and a rapid onset of action.
DrugBank Indication: For use during the induction and maintenance of general anesthesia.
Targets:
Therapeutic Category:
Clinical Trial Progress:
Latest Progress: